News file for: Eisai Group
The Eisai Access to Medicines Navigator provides information on neglected tropical diseases for patients and healthcare professionals.
Otsuka Pharmaceutical acquires two drugs, Dacogen® and E7727, from Eisai Co. to enhance their leukemia drug portfolio.
Japan’s Global Health Initiative Technology Fund has committed US$12 million in grants for neglected diseases and a potential tuberculosis vaccine.
Eisai Co., Ltd. has entered into an agreement with the Broad Institute to develop new therapeutic agents for the treatment of neglected tropical diseases and tuberculosis.
The Global Health Innovative Technology Fund, a new public-private partnership, is taking Japanese R&D to the global fight against infectious disease.
Eisai Co. Ltd. announced today that it has received Russian regulatory approval for its antiepileptic drug, Zonegran (zonisamide).
A large coalition of pharmas, governments, and NGOs have announced their goal of eliminating or controlling 10 neglected tropical diseases by 2020.
IBM has opened a branch office in Visakhapatnam, Southeast India as part of the company’s continued geographic expansion initiative to increase its presence in key growth markets.